TNFSF15 and colitis: Treatment of Ulcerative colitis (UC) patients with anti-TL1A antibody has been shown to reduce expression of fibrotic pathway markers, including matrix metalloproteinases (MMP7 and MMP10) (72), and treatment of the induced colitis mouse model with anti-TL1A antibody led not only to the reduction but also to the reversal of collagen deposition in mice with established fibrosis (73).